← Back to Search

Other

Platelet-Rich-Plasma (PRP) for Erectile Dysfunction

Q: Does this trial include individuals above the age of 50 in its recruitment criteria?

Eligible candidates for this research endeavor are individuals aged between 30 and 70 years. There are separate studies available for participants under the age of 18, as well as a distinct cohort targeting those above the age of 65, with a total enrollment capacity of 60 participants in this category.

Q: What criteria must individuals meet in order to be eligible for participation in this clinical study?

Individuals aged between 30 and 70 years old with <a href="https://www.withpower.com/clinical-trials/erectile-dysfunction">erectile dysfunction</a> are eligible to participate in this study, which aims to enroll approximately 60 participants.

Q: Is this medical study currently accepting participants for enrollment?

As per clinicaltrials.gov, the current trial is not in a recruitment phase. It was first listed on March 1st, 2024, with the most recent update made on February 9th of the same year. Despite this specific study not accepting participants presently, there are numerous other trials seeking candidates actively - totaling at least 66 ongoing studies.

Q: What is the safety profile of Platelet-Rich-Plasma (PRP) for individuals?

Based on our evaluation at Power, the safety rating for Platelet-Rich-Plasma (<a href="https://www.withpower.com/clinical-trials/prp">PRP</a>) is designated as 1. This score reflects the early Phase 1 nature of the trial where there exists only a modest body of data supporting both safety and efficacy.

Phase 1

Waitlist Available

Research Sponsored by University of Manitoba

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Males between >30 and <70 years of age with erectile dysfunction (ED) based on IIEF scores (score between 16 and 25)

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1, 3, 6 months post-procedure

Awards & highlights

Study Summary

"This trial is looking at different therapies like platelet-rich plasma injections, shockwave therapy, and stem cell therapy for erectile dysfunction. While these treatments are non-invasive, there is still limited data on

Who is the study for?

This trial is for men experiencing erectile dysfunction. Participants should be seeking a non-invasive treatment option and have not found success with other therapies. Specific eligibility criteria are not provided, but typically include age range, health status, and the severity of ED.Check my eligibility

What is being tested?

The study is testing the effectiveness of Platelet-Rich-Plasma (PRP) injections compared to saline (a placebo) in treating erectile dysfunction. It's Canada's first pilot randomized controlled trial on PRP for ED, aiming to see if it can improve underlying tissue and nerve function.See study design

What are the potential side effects?

While specific side effects are not listed here, PRP generally has minimal side effects since it uses the patient’s own blood. However, potential risks may include pain at injection site, infection or no improvement in ED symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am a man aged 31-69 with mild to moderate erectile dysfunction.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1, 3, 6 months post-procedure

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1, 3, 6 months post-procedure

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1, 3, 6 months post-procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

International Index of Erectile Function (IIEF)

Secondary outcome measures

Adverse Events

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Platelet-Rich-Plasma (PRP)Experimental Treatment1 Intervention

PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.

Group II: SalinePlacebo Group1 Intervention

Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.

0 / 1Eligibility criteria met

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of ManitobaLead Sponsor

595 Previous Clinical Trials

199,462 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this trial include individuals above the age of 50 in its recruitment criteria?

"Eligible candidates for this research endeavor are individuals aged between 30 and 70 years. There are separate studies available for participants under the age of 18, as well as a distinct cohort targeting those above the age of 65, with a total enrollment capacity of 60 participants in this category."

Answered by AI

What criteria must individuals meet in order to be eligible for participation in this clinical study?

"Individuals aged between 30 and 70 years old with erectile dysfunction are eligible to participate in this study, which aims to enroll approximately 60 participants."

Answered by AI

Is this medical study currently accepting participants for enrollment?

"As per clinicaltrials.gov, the current trial is not in a recruitment phase. It was first listed on March 1st, 2024, with the most recent update made on February 9th of the same year. Despite this specific study not accepting participants presently, there are numerous other trials seeking candidates actively - totaling at least 66 ongoing studies."

Answered by AI

What is the safety profile of Platelet-Rich-Plasma (PRP) for individuals?

"Based on our evaluation at Power, the safety rating for Platelet-Rich-Plasma (PRP) is designated as 1. This score reflects the early Phase 1 nature of the trial where there exists only a modest body of data supporting both safety and efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Evaluating the Efficacy of Platelet-Rich-Plasma (PRP) for Erectile Dysfunction

Premal Patel, MD 2024. "Evaluating the Efficacy of Platelet-Rich-Plasma (PRP) for Erectile Dysfunction". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06264635.

All > Erectile Dysfunction